SCHEMBL3508533

SCHEMBL3508533

Cc1cc(Nc2ncnc3ccn(CCNC(=O)CC(C)(C)O)c23)ccc1Oc1cccc(OCC2CC2)c1

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.66
ERBB2 P04626 19/20 0.66
ERBB4 Q15303 8/20 0.66
ERBB3 P21860 7/20 0.66
LCK P06239 2/20 0.66
LYN P07948 2/20 0.66
MET P08581 2/20 0.66
CSK P41240 2/20 0.66
MAP2K1 Q02750 2/20 0.66
AURKB Q96GD4 2/20 0.66
BMPR1B O00238 1/20 0.66
EPHB6 O15197 1/20 0.66
MAP2K5 Q13163 1/20 0.66
NLK Q9UBE8 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506345 0.93 EGFR (0.77) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL3508545 0.91 EGFR (0.55) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL13423843 0.89 EGFR (0.71) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL3508833 0.89 EGFR (0.69) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL3506701 0.89 EGFR (0.67) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL2748884 0.88 EGFR (0.72) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL2749509 0.87 EGFR (0.85) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL13226139 0.86 EGFR (0.69) EGFRERBB2ERBB4ERBB3LCK
SCHEMBL3505164 0.86 EGFR (0.62) EGFRERBB2ERBB4ERBB3
Hydrochloric Acid SCHEMBL3506582 0.86 EGFR (0.69) EGFRERBB2ERBB4ERBB3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216788-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
US-20100216788-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
WO-2007064045-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216788-A1 FUSED HETEROCYCLIC COMPOUND GRK6, FGFR1, PTK6 EGFR 54/4885ERBB2 31/4885ERBB4 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.